# US 2016/0250049 A1 · Methods of Treatment with Drug Eluting Stents with Prolonged Local Elution Profiles with High Local Concentrations and Low Systemic Concentrations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250049 A1
- Document ID: US20160250049A1
- Status: Published application
- Kind: A1
- Application number: 15/154,773
- Filed: 2016-05-13
- Published: 2016-09-01
- Earliest claimed: 2007-05-01
- Assignees: Abbott Laboratories
- Applicants: Abbott Laboratories
- Inventors: Kent C.B. STALKER; Winnette S. MCINTOSH; Dudley S. JAYASINGHE; Gregory C. ORR; John E. PAPP; Lewis B. SCHWARTZ
- Web page: https://patentgrep.com/patent/US20160250049A1

## CPC

- A61F 2/915: with bands having a meander structure, adjacent bands being connected to each other
- A61F 2/06: Blood vessels
- A61L 31/022: {Metals or alloys}
- A61L 31/10: Macromolecular materials
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61F 2002/91541: {Adjacent bands are arranged out of phase}
- A61F 2002/91583: {by a bridge, whereby at least one of its ends is connected along the length of a strut between two consecutive apices within a band}
- A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2420/08: Coatings comprising two or more layers
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A drug eluting stent can include a stent body having a polymeric coating with a lipophilic and/or hydrophilic element. A drug that has a bioactivity that inhibits cell proliferation can be disposed in the polymeric coating. The drug can be present in the polymer at an amount greater than or equal to about 150 μg/cm2. The polymeric coating and drug are configured to cooperate so as to form a diffusion pathway with tissue when the stent is disposed in a body lumen such that the drug preferentially diffuses into the tissue over a body fluid passing through the body lumen such that a maximum systemic blood concentration of the drug is less than about 40 ng/ml.

## Claims

### Claim 1

A method of treating peripheral vascular disease in a subject, the method comprising:
implanting in a peripheral artery of a subject a drug eluting stent comprising:
a stent body of about 130 mm to about 170 mm in length, the stent body being a design of annular elements and interconnectors where the annular elements are connected adjacently by at least one interconnector;
a polymeric coating disposed on the stent body, the polymeric coating being 2 μm to 50 μm in thickness; and
a lipophilic drug disposed in the polymeric coating, the lipophilic drug being present at an amount between about 4 mg to about 8 mg;
wherein the maximum systemic blood concentration of the lipophilic drug in the subject is about 30 ng/ml or less than 30 ng/ml.

### Claim 2 (depends on 1)

The method as in claim 1, wherein the lipophilic drug is present in an amount greater than or equal to 200 μg/cm2.

### Claim 3 (depends on 1)

The method as in claim 1, wherein the lipophilic drug is everolimus, zotarolimus, tacrolimus, paclitaxel, or a combination thereof.

### Claim 4 (depends on 3)

The method as in claim 3, wherein the lipophilic drug is present at an amount between about 5 mg and about 7 mg.

### Claim 5 (depends on 1)

The method as in claim 1, wherein the lipophilic drug is present at an amount between about 5 mg and about 7 mg.

### Claim 6 (depends on 1)

The method as in claim 1, wherein the polymeric coating ranges from about 4 μm to about 25 μm in thickness.

### Claim 7 (depends on 1)

The method as in claim 1, wherein the polymeric coating comprises a primer layer disposed on the stent body, a drug-loaded layer disposed on the primer layer, and a topcoat layer disposed on the drug-loaded layer.

### Claim 8 (depends on 7)

The method as in claim 7, wherein the polymeric coating is characterized by at least one of the following:
the primer layer being from about 1% to about 20% of the total coating thickness;
the drug-loaded layer being from about 25% to about 90% of the total coating thickness; or
the topcoat being from about 5% to about 50% of the total coating thickness.

### Claim 9 (depends on 8)

The method as in claim 8, wherein the stent body is nitinol, the lipophilic drug is everolimus, and the polymer of the polymeric coating is an ethylenevinylalcohol copolymer.

### Claim 10 (depends on 1)

The method as in claim 1, wherein the lipophilic drug is everolimus.

### Claim 11 (depends on 4)

The method as in claim 4, wherein the lipophilic drug is everolimus.

### Claim 12 (depends on 1)

The method as in claim 1, wherein the lipophilic drug is zotarolimus.

### Claim 13 (depends on 4)

The method as in claim 4, wherein the lipophilic drug is zotarolimus.

### Claim 14 (depends on 1)

The method as in claim 1, wherein the lipophilic drug is paclitaxel.

### Claim 15 (depends on 4)

The method as in claim 4, wherein the lipophilic drug is paclitaxel.

### Claim 16 (depends on 1)

The method as in claim 1, wherein the maximum systemic blood concentration of the lipophilic drug in the subject is about 20 ng/ml or less than 20 ng/ml.

### Claim 17 (depends on 1)

The method as in claim 1, wherein the maximum systemic blood concentration of the lipophilic drug in the subject is about 10 ng/ml or less than 10 ng/ml.

### Claim 18 (depends on 1)

The method as in claim 1, wherein the stent body is formed from Nitinol.

### Claim 19 (depends on 1)

The method as in claim 1, wherein the peripheral artery of the subject into which the stent is implanted is a superficial femoral artery.

### Claim 20 (depends on 1)

The method as in claim 1, wherein the peripheral artery of the subject into which the stent is implanted is an iliofemoral artery.
